Nabla Bio is an autoverse platform of proprietary biologically informed machine learning that co-develops antibody drugs.
Employees: 1-10
Total raised: $37M
Founders name: Frances Anastassacos; Surge Biswas
Founders Related Locations: United States, Massachusetts, Boston
Investors 2
| Date | Name | Website |
| 20.04.2022 | Khosla Ven... | khoslavent... |
| 29.08.2021 | Y Combinat... | ycombinato... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.05.2024 | Series A | $26M | - |
| 10.12.2021 | Seed | $11M | - |
Persons 9
| Date | First Name | Last Name | Title | Location | |||
| - | Mark | DeSimone | Senior Res... | linkedin.c... | - | m**k@nabla... | - |
| - | Sunita | Subramania... | Senior Sci... | linkedin.c... | - | s****a@nab... | - |
| - | Surge | Biswas | Co-founder... | linkedin.c... | - | - | United Sta... |
| - | Payton | Utzman | Senior Res... | linkedin.c... | - | p****n@nab... | - |
| - | Devashish | Prasad | Associate ... | linkedin.c... | - | d*******h@... | - |
| - | Adithya | Paramasiva... | Associate ... | linkedin.c... | - | a*****a@na... | - |
| - | Frances | Anastassac... | Cofounder | linkedin.c... | - | f*****s@na... | - |
| - | Owen | Morrissey | Software E... | linkedin.c... | - | o**n@nabla... | - |
| - | Karmanya | Aggarwal | ML Scienti... | linkedin.c... | - | k******a@n... | - |
Mentions in press and media 14
| Date | Title | Description |
| 15.05.2024 | Nabla Bio Secures $26M Series A Funding | Nabla Bio, a Cambridge, MA-based company developing AI and wet-lab technologies, raised $26M in Series A funding. The round was led by Radical Ventures with participation from all existing investors, and strategic collaborations with AstraZ... |
| 07.12.2021 | Nabla Bio raises $11M for an “end-to-end” antibody design platform | Nabla Bio, a Boston, Massachusetts based startup, announced a $11 million seed round on Monday. The company, founded in May 2020, is looking to enter the increasingly competitive space of antibody design, and manufacturing. Nabla Bio, in es... |
| 07.12.2021 | Harvard spinout Nabla Bio nabs $11M for AI-driven antibody design | After a decades-long tenure as the so-called father of synthetic biology, George Church, Ph.D., has developed something of a Midas touch when it comes to biotech and medtech startups. Among the latest of the serial entrepreneur’s projects i... |
| 07.12.2021 | Harvard spinout Nabla Bio nabs $11M for AI-driven antibody design | After a decades-long tenure as the so-called father of synthetic biology, George Church, Ph.D., has developed something of a Midas touch when it comes to biotech and medtech startups. Church and his team have gotten an early boost for the y... |
| 06.12.2021 | Nabla Bio Closes $11M Seed Financing led by Khosla Ventures and Zetta Venture Partners | – Top-tier investor syndicate co-led by Khosla Ventures and Zetta Venture Partners, with participation from Fifty Years and Cantos Ventures. – Financing will be used to develop an AI-first protein design platform that enables the rapid end-... |
| 06.12.2021 | Nabla Bio Closes $11M Seed Financing | BOSTON, NY, Nabla Bio, an antibody design company, announced the closing of an $11M Seed financing round. >> Click here for more funding data on Nabla Bio >> To export Nabla Bio funding data to PDF and Excel, click here N... |
| 06.12.2021 | Better.com’s morale and SPAC merger success in question after CEO’s unruly comments | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Good morning, Term Sheeters. Paid Content How A.I. can reshape jobs to enable more value-add From... |
| 06.12.2021 | Harvard spinout Nabla Bio lands $11M to bring AI technology to antibody design | Software is key to how therapeutic antibodies are discovered today. The founders of Nabla Bio say the next generation of antibodies will be designed rather than discovered, and these designs will be aided by artificial intelligence. The Har... |
| 06.12.2021 | Nabla Bio Raises $11M in Seed Financing | Nabla Bio, a Boston MA-based antibody design company, raised $11M in Seed funding. The round was led by Khosla Ventures and Zetta Venture Partners with participation from Fifty Years and Cantos Ventures. The company intends to use the funds... |
| 06.12.2021 | Nabla Bio Closes $11M Seed Financing led by Khosla Ventures and Zetta Venture Partners | Nabla Bio, a next-generation antibody design company, announced the closing of a $11M Seed financing round. The round was co-led by Khosla Ventures and Zetta Venture Partners, with participation from Fifty Years, Cantos Ventures, and others... |
Show more